Aachen, 08 July 2026 – Grünenthal, a global leader in pain management and related diseases, announced today that their investigational compound tegacorat (GRM-01) has received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD). Tegacorat, a non-steroidal Selective Glucocorticoid Receptor Agonist…
No responses yet